with n-HFL patients comparing the use of filgrastim after peripheral blood progenitor cells reinfusion. METHODS: Multi-centre study conducted in France between 1995-1999 including 51 patients (24 placebo (P) and 27 filgrastim (FI)). Demographic, disease and treatment-specific information was collected through the CRF. QoL assessment per patient over 90 days of followup (FU) was calculated as follows. QoL-index valued from 0 (worst) to 1 (best) was used to assign QoL per hospital day: in sterile room (SR) ϭ 0.6; in a normal room (NR) ϭ 0.9. Each adverse event (AE) (WHO grade 3 or 4) affected the QoL index with an additional factor of 0.8, 0.6, 0.4 or 0.2 respectively for 1, 2, 3, у 4 concomitant AEs per patient per day. Average QoL-scores over time per treatment arm were compared using KaplanMeier statistics (p Ͻ .05, two-sided). Sensitivity analysis on the score index over the FU was undertaken. RESULTS: For FI the average days with 0, 1, 2, 3, ജ4 AEs in a SR was 6.59, 4, 2.56, 0.81, 0.37 and in a NR, 1.59, 1.67, 0.56, 0.11, 0. For P in a SR we had respectively 8. 
OBJECTIVE:
It is assumed that genetic testing for breastovarian cancer predisposition in the context of peer-reviewed research protocols at academic centers offers protection against test-related distress. However, BRCA1/2 genetic testing under research protocols often implies a significant time delay before the test result can be disclosed, which would not apply to commercially available testing. Using data from our own research setting, we investigated whether delay in getting BRCA1/2 test results was associated with participants' distress. METHODS: Participants were 128 women from 26 French Canadian kindred with a BRCA1/2 germline mutation identified. Genetic counseling was provided in a pre-test education session and a result disclosure session. Of the women tested, 53 (41%) were found to be carriers of the familial mutation and 75 (59%), non-carriers. Mean age at enrollment (48.4 yrs Ϯ 12.1) was similar for the two groups. Test-related distress was assessed by the Impact of Event Scale one month after result disclosure. RESULTS: Time interval between blood sample for testing and result disclosure varied considerably (range: 35 to 756 days), and was similar for carriers (mean ϭ 172 Ϯ 120 days) and non-carriers (mean ϭ 174 Ϯ 174 days). Among non-carriers, those given their result less than six months following blood draw (n ϭ 48) tended to have lower levels of test-related distress (mean ϭ 3.3 Ϯ 5.2) than those who were told their result beyond 6 months (n ϭ 27, mean ϭ 7.8 Ϯ 11.2, p ϭ 0.06). For carriers, testrelated distress did not differ according to whether they were given their result less than six months (n ϭ 35, mean ϭ 10.4 Ϯ 13.7) after the blood draw or later (n ϭ 18, mean ϭ 9.8 Ϯ 12.2). CONCLUSIONS: Consistent with others, these results indicate that most women cope well with test information in research settings with careful expert counseling. Nevertheless, our findings among non-carriers suggest that prompt disclosure of BRCA1/2 test results has potential quality-of-life benefits. 
PCN17

PSYCHOMETRIC PROPERTIES OF THE EORTC QUALITY OF LIFE CORE QUESTIONNAIRE (QLQ-C30) IN EORTC TRIALS
OBJECTIVE:
The EORTC QLQ-C30 is one of the most widely used QL measures in cancer clinical trials. This study aimed to look at the psychometric properties of the QLQ-C30 in 32 countries with a database of 9000 patients. METHOD: All EORTC studies incorporating the EORTC QLQ-30 were systematically selected for this study. Inclusion criteria for trials were if the trial containing the QLQ-C30 responses had been coded into the EORTC database. One hundred fourteen EORTC studies were reviewed of which 52 met the criteria for being included in the final analysis. RESULTS: The majority of cancer patients were receiving palliative care for primary cancers including melanoma, prostate, head and neck, breast and lung cancers and 90% of the patients were distributed over 10 out of the 32 countries. At least one item of data was missing in 14 to 17% of patient questionnaires completed, though the average percentage of missing items per patient ranged from 1.1% to 1.5% Particular items relating to Role Functioning and Financial Difficulties were the most common items missing (3%). Factor analyses for all three versions of the questionnaire are similar, though some difference has been found when examining individual cancers. Inter-domain correlations in each of the three versions of the QLQ-C30 were strongest in Role Functioning, Pain and Global Health Status. Cronbach's reliability measure shows improved reliability in newer versions of the questionnaire, for example, the pain scale increases from 0.82 to 0.86 from version 1 to version 3. CONCLUSION: We believe this is one of the first studies to examine the scales of all three versions of the QLQ-C30 with a large sample across a large number of countries and cancer sites. We found that in general all three versions of the QLQ-C30 have similar psychometric structures, that the measure proves to a be a useful tool to use within a clinical trial setting and that missing data is continually reducing over time, indicating increasing compliance among staff/patients. (QOL) is becoming an accepted endpoint in cancer clinical trials. However, reports suggest that fewer than 10% of clinical trials include QOL assessment, it is believed that such reports may be biased by time lag. This paper examines the extent of QOL studies that are conducted within one of the largest academic cancer clinical trial organizations in Europe. METHOD: Examination of all clinical trials conducted by the EORTC (between 1990 to 2000) was undertaken by reviewing databases, records and publications. Trials were systematically selected if they involved any aspect of QOL assessment. The protocols were then evaluated using criteria that evaluated the quality of trial designs and methodology employed. RESULTS: In total, 112 clinical trials involving over 10,000 patients were identified as having a QOL component. All trials involved multinational patient recruitment, with the highest recruitment from the Netherlands, France and Germany, and lowest from Malta, Estonia and Slovakia. Approximately 25 disease groups have been actively recruiting patients from disease groups of genito-urinary, breast and lung cancers. A clear linear trend was noted, with increasing numbers of clinical trials involving QOL components over this period. Of these trials, 74 studies were Phase III, 15 Phase II and the remainder were feasibility studies. Presently, 45 trials are ongoing, 19 almost ready for data analysis, 15 published and 10 being analyzed. In the last year, 30 studies involving QOL assessment have been submitted for research, suggesting that QOL is a highly important endpoint in trials throughout Europe CONCLUSION: While a decade ago QOL was not a major component of EORTC clinical trials, it is now highly integrated into trials, almost a standard secondary endpoint. In the European context, this suggests that clinicians and researchers are increasingly seeing the importance of patient-based outcome assessment methods.
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QUALITY OF LIFE IN CANCER CLINICAL TRIALS -AN OVERVIEW OF APPROACHES WITHIN THE EORTC
